# US 2005/0090531 A1 · MAG expression promoters

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0090531 A1
- Document ID: US20050090531A1
- Status: Published application
- Kind: A1
- Application number: 10/969,885
- Filed: 2004-10-22
- Published: 2005-04-28
- Earliest claimed: 1999-05-25
- Assignees: Mitsubishi Pharma Corporation
- Inventors: Masakazu Kawasaki; Nobuharu Gotoh; Yoshiharu Hayashi; Kazuyuki Kawasaki
- Web page: https://patentgrep.com/patent/US20050090531A1

## CPC

- C07D 249/08: 1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- A61K 31/4164: 1,3-Diazoles
- A61K 31/4174: Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07D 231/12: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 233/56: with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The MAG expression promoter of the present invention contains a compound of the formula (I) wherein each symbol is as defined in the specification, an optically active form thereof or a pharmaceutically acceptable salt thereof. As a compound of the formula (1), 4-[α-hydroxy-5-(1-imidazolyl)-2-methylbenzyl]-3,5-dimethylbenzoic acid is exemplified. The MAG expression promoter of the present invention is useful as an agent for the prophylaxis and/or treatment of a disease of mammals inclusive of humans, which mainly presents hypomyelination, further, dysmyelination or demyelination.

## Claims

### Claim 1

A MAG method of promoting expression of MAG comprising administering a compound of the formula (I)
wherein
R1 is a hydrogen atom, a halogen atom, an alkyl group or an alkoxy group;
R2 and R3 are the same or different and each is a hydrogen atom or an alkyl group;
R4 is an alkyl group, —COOH, —COOR5, —CONR6R7, —CH2NR 6R7, —CH2OH or —CH2OR8;
wherein R5 and R8 are each an alkyl group, and R6 and R7 are the same or different and each is a hydrogen atom or an alkyl group, or R6 and R7 in combination form imidazole together with the adjacent nitrogen atom;
A is —CH(OH)—, —C(═O)— or —CH2—; and
Z is ═CH— or ═N—,
an optically active form thereof or a pharmaceutically acceptable salt thereof to a mammal.

### Claim at position 2

2-9. (canceled)

### Claim 10

A method for promoting a mvelination of axon, which method comprises administering a compound of the formula (I)
wherein
R1 is a hydrogen atom, a halogen atom, an alkyl group or an alkoxy group;
R2 and R3 are the same or different and each is a hydrogen atom or an alkyl group;
R4 is an alkyl group, —COOH, —COOR5, —CONR6R7, —CH2NR6R7, —CH2OH or —CH2OR8;
wherein R5 and R8 are each an alkyl group, and R6 and R7 are the same or different and each is a hydrogen atom or an alkyl group, or R6 and R7 in combination form imidazole together with the adjacent nitrogen atom;
A is —CH(OH)—, —C(=O)— or —CH2—; and
Z is ═CH— or ═N—,
an optically active form thereof or a pharmaceutically acceptable salt thereof to a mammal.

### Claim 11 (depends on 10)

The method of claim 10, wherein, in the formula (I), R1 is a halogen atom, an alkyl group or an alkoxy group.

### Claim 12

A method for promoting a mvelination. of axon, which method comprises administering 4-[α-hydroxy-5-(1-imidazolyl)-2-methylbenzyl]-3,5-dimethylbenzoic acid, an optically active form thereof or a pharmaceutically acceptable salt thereof to a mammal.

### Claim 13

A method for promoting a myclination of axon, which method comprises administering a compound of the formula (I)
wherein
R1 is a hydrogen atom, a halogen atom, an alkyl group or an alkoxy group;
R2 and R3 are the same or different and each is a hydrogen atom or an alkyl group;
R4 is an alkyl group, —COOH, —COOR5, —CONR6R7, —CH2NR6R7, -CH2OH or —CH2OR8;
wherein R5 and R8 are each an alkyl group, and R6 and R7 are the same or different and each is a hydrogen atom or an alkyl group, or R6 and R7 in combination form imidazole together with the adjacent nitrogen atom;
A is —CH(OH)—, —C(═O)— or —CH2—; and
Z is =CH— or ═N—,
an optically active form thereof or a pharmaceutically acceptable salt thereof a nammal.

### Claim 14 (depends on 13)

The method of claim 13, wherein, in the formula (I), R1 is a halogen atom, an alkyl group or an alkoxy group.

### Claim 15

A method for promoting a myelination of axon, which method comprises administering 4-[α-hydroxy-5-(1-imidazolyl)-2-methylbenzyl]-3,5-dimethylbenzoic acid, an optically active form thereof or a pharmaceutically acceptable salt thereof to a mammal.

### Claim at position 9

16-33. (canceled)

### Claim 34 (depends on 10)

The method of claim 10, wherein the mammal is a human.

### Claim 35 (depends on 12)

The method of claim 12, wherein the mammal is a human.

### Claim 36 (depends on 13)

The method of claim 13, wherein the mammal is a human.

### Claim 37 (depends on 15)

The method of claim 15, wherein the mammal is a human.
